Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-Breast.

Julia Foldi¹, Gregory Hogan², Katherine Johansen Taber², Matthew LaBella², Britney Sadler², Ravi Patel², Marija Balic¹, Derrick Haslem³, Marcela Mazo Canola⁴, Judy Peih-Ying Tsai⁵, Therese Cusick⁶, Niyati Nathwani⁷, Yoichi Naito⁸, Chikako Funasaka⁹, Karlton Wong¹⁰, Alexander Ham², Ashley Acevedo², C J Battey², Genevieve M Gould², Dale Muzzey², Jeff Jasper²

¹Department of Medicine, Division of Malignant Hematology and Medical Oncology, University of Pittsburgh Medical Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

²Research and Development, Myriad Genetics, Salt Lake City, UT, USA.

³Oncology Service Line, Intermountain Healthcare, Saint George, UT, USA.

⁴Division of Hematology and Oncology, Mays Cancer Center, University of Texas at San Antonio, San Antonio, TX, USA.

⁵Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.

⁶Department of Surgery, Ascension Via Christi Hospitals Wichita, Inc.., Wichita, KS, USA.

⁷Carolina Blood and Cancer Care Associates, Lancaster, SC, USA.

⁸Department of Medical Oncology, Department of General Internal Medicine, Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.

⁹Department of Medical Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.

¹⁰Department of Medical Oncology, Providence Saint Joseph's Medical Center, Burbank, CA, USA.

PubMed DOI

Abstract

PURPOSE: Pathological complete response (pCR) after neoadjuvant therapy (NAT) strongly associates with reduced breast cancer relapse risk. Circulating tumor DNA (ctDNA) shows promise as a therapy-response biomarker, but prior studies had limited sampling and assay sensitivity. MONITOR-Breast characterized ctDNA dynamics across NAT at high temporal resolution using an ultrasensitive molecular resid…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.